Kendall Law Group, led by former federal judge Joe Kendall, is investigating Synergetics USA, Inc. (NASDAQ: SURG) and its Board of Directors on behalf of shareholders in connection with the proposed sale to Valeant Pharmaceuticals International, Inc. (NYSE: VRX). According to the terms of the agreement, Synergetics shareholders will receive $6.50 for each share of Synergetics common stock held. In addition to this cash payment, Synergetics stockholders may receive an additional cash payment of up to a $1.00 per share if certain specified sales milestones are achieved following the closing.

The national securities firm’s investigation seeks to determine whether Synergetics and its Board breached their fiduciary duties by engaging in self-dealing, failing to maximize the value of the Company, failing to disclose all material benefits and costs, and failing to obtain the best possible consideration for the Synergetics shareholders.

If you currently own shares of Synergetics and want to know more about your rights, you are encouraged to contact Jamie McKey at the Kendall Law Group at 877-744-3728 or by email at jmckey@kendalllawgroup.com to learn more about your rights as a shareholder. There is no cost or obligation to you. Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in nationwide complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.